Thank you for subscribing!
Finfeed Archived May 13, 2019
Shares in Genetic Technologies Ltd (ASX:GTG; NASDAQ:GENE) surged nearly 60% on Friday after the company announced two new ground-breaking cancer risk assessment tests had been completed and validated.
Finfeed Archived May 07, 2019
Genetic Technologies Ltd (ASX:GTG) has established a Memorandum of Understanding with TGen, an Arizona-based biomedical research institute dedicated to conducting ground-breaking research with life changing results.
Next Investors Archived Apr 08, 2019
Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.
Finfeed Archived Apr 08, 2019
Genetic Technologies Ltd (ASX:GTG), a provider of world-leading genetic risk assessment test products, has established an important MoU with TGen, a major player in the US biomedical research industry.
Get expert stock analysis direct in your inbox
Finfeed Archived Apr 02, 2019
Imugene Limited (ASX:IMU), a leading clinical stage immuno-oncology company, has today released new data on the Phase lb study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia.
Finfeed Archived Mar 14, 2019
Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced dosing of the first patient in a in 68 patient randomised Phase 2 HER-Vaxx cancer trial.
Finfeed Archived Feb 28, 2019
Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors.
Next Investors Archived Jan 31, 2019
Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.
Finfeed Archived Jan 07, 2019
Imugene (ASX:IMU) has appointed world-renowned cancer researcher, Professor Michael Caligiuri — President of the City of Hope National Medical Center in LA — to its Scientific Advisory Board (SAB).
Finfeed Archived Dec 17, 2018
Imugene (ASX:IMU) has met all study endpoints and produced positive top-line results from its Phase 1b study of its HER-Vaxx gastric cancer vaccine.
Finfeed Archived Dec 05, 2018
Long living tortoises may be the key to curing cancer and living longer.
Finfeed Archived Nov 19, 2018
Immuron (ASX:IMC) has just appointed a well-credentialled CEO to help it develop and commercialise its many treatments of many gut mediated diseases.
Finfeed Archived Nov 13, 2018
Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced preparations are underway to begin the Phase 2 study of its HER-Vaxx cancer vaccine in gastric cancer patients in early 2019.
Finfeed Archived Nov 09, 2018
Imugene Limited (ASX:IMU) has today announced that it has received a research and development (R&D) tax refund of $1.85 million as part of the Australian government’s R&D tax incentive scheme. The incentive recognises the important immuno-oncology research activities undertaken by the ASX small cap during the financial year ended 30 June 2018.
Finfeed Archived Nov 01, 2018
Race Oncology (ASX:RAC) has come to agreement with Biosynergy to pursue licensing deals for chemotherapy drug, Bisantrene.
Next Investors Archived Oct 30, 2018
Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.
Finfeed Archived Oct 29, 2018
Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX), has appointed leading drug discovery and development executive, Dr James Winkler, as Vice President for business development based in the US.
Finfeed Archived Oct 24, 2018
Rhythm Bioscences (ASX:RHY) surged in share price under expectation that it will successfully complete the next phase of its key reagent development program by the end of 2018.
Join Our Mailing List
